IsPETase-4 * Chimera recombinase as well as coding gene, recombinant plasmid, engineering bacterium and application of IsPETase-4 * Chimera recombinase

By performing a specific replacement design in the amino acid sequence of IsPETase, IsPETase-4×Chimera recombinase was obtained, which solved the problems of low activity and poor thermal stability of PET hydrolase at room temperature, and achieved efficient PET degradation at high temperatures, significantly Increased TPA production.

CN119032167APending Publication Date: 2024-11-26BEIJING MEIHAO BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202480001856.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-09-28
Filing Date
2024-01-15
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing PET hydrolase has low activity and poor thermal stability at room temperature, and cannot effectively degrade PET plastics in the natural environment, limiting its practical application.

Method used

A IsPETase-4×Chimera recombinase was designed to improve the activity and thermal stability of the enzyme by replacing specific amino acids in the amino acid sequence of IsPETase, including SEQ ID No.1, SEQ ID No.2, SEQ ID The amino acid sequences of No.3 and SEQ ID No.4 were replaced to form a high activity and thermal stability IsPETase-4×Chimera recombinase.

Benefits of technology

IsPETase-4×Chimera recombinase maintains high efficiency activity at high temperatures, the hot melting temperature increases to 73.18℃, and the TPA yield increases significantly, which is far higher than the natural PET hydrolase, achieving efficient degradation of PET.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005038612330000121
    Figure BDA0005038612330000121
  • Figure BDA0005038612330000131
    Figure BDA0005038612330000131
  • Figure BDA0005038612330000132
    Figure BDA0005038612330000132
Patent Text Reader

Abstract

The invention provides IsPETase-4 * Chimera recombinase as well as a coding gene, a recombinant plasmid, an engineering bacterium and application thereof. According to the IsPETase-4 * Chimera recombinase, at least one of amino acid sequences shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4 is replaced on the basis of IsPETase, and compared with natural PET hydrolase, the IsPETase-4 * Chimera recombinase has high activity and heat stability and has application value for achieving efficient degradation of PET. The invention also provides a coding gene for coding the recombinase, a recombinant plasmid containing the coding gene and an engineering bacterium containing the recombinant plasmid.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This patent application claims the priority of Chinese patent application No. CN 202311275016.9 filed on September 28, 2023. The disclosure of the prior application is incorporated into this application by reference in its entirety. Technical Field

[0002] The present application relates to the field of enzyme engineering technology, and specifically to an IsPETase-4×Chimera recombinase and its encoding gene, recombinant plasmid, engineering bacteria and application. Background Art

[0003] With the increase in plastic consumption, the impact of plastic waste on the environment has attracted widespread attention worldwide. Polyethylene terephthalate (PET) is currently the most in-demand polyester plastic. Generally speaking, the main methods for treating PET include landfill, incineration, pyrolysis and chemical degradation, all of which consume a lot of energy and may cause secondary pollution. However, since PET is made of terephthalic acid (TPA) and ethylene glycol (EG) connected by ester bonds, it can be decomposed by the hydrolysis of various enzymes, such as lipase and cutinase. If PET is degraded and TPA is recycled, not only can the impact of PET on the environment be reduced, but the recycled TPA can also bring additional social and economic benefits. Therefore, completely depolymerizing PET into monomers is a necessary step to reduce environmental pollution caused by PET and obtain high value-added products TPA.

[0004] Biological treatment technology has been gradually applied to the treatment of waste plastics due to its high efficiency, low cost and environmental friendliness. In the past few years, enzyme-based technology has made significant progress in the treatment of PET waste, providing a new option that is environmentally friendly and cost-effective. A variety of enzymes that can hydrolyze PET have been discovered, such as esterases, lipases and cutinases. However, the activity of these PET hydrolases at room temperature is very low, so it is impossible to degrade the remaining PET plastics in situ in the natural environment. PETase from the bacterium Ideonella sakaiensis, also known as IsPETase, is an enzyme that degrades PET. It can effectively hydrolyze PET into TPA and other products at room temperature. However, its thermal stability and activity at high temperatures are poor, which still limits its practical application. Summary of the invention

[0005] In response to the above technical problems, the present application provides an IsPETase chimera (IsPETase-4×Chimera recombinant enzyme) and its encoding gene, recombinant plasmid, engineered bacteria and application. The recombinant enzyme has high activity and thermal stability, which makes up for the shortcomings of existing natural PET hydrolases.

[0006] In order to achieve the above application purpose, this application adopts the following technical solutions:

[0007] In a first aspect, the present application provides an IsPETase-4×Chimera recombinase, wherein the IsPETase-4×Chimera recombinase has an amino acid sequence of: IsPETase (amino acid sequence as shown in SEQ ID No.13) is replaced with at least one of the amino acid sequences shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4, wherein:

[0008] The amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5 or SEQ ID No.6;

[0009] The amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7 or SEQ ID No.8;

[0010] The amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9 or SEQ ID No.10;

[0011] The amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11 or SEQ ID No.12.

[0012] It should be noted that the amino acid sequence shown in SEQ ID No.1 is a partial sequence of IsPETase (amino acid sequence as shown in SEQ ID No.13). Similarly, the amino acid sequences shown in SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4 are also partial sequences of IsPETase. The peptide consisting of the first 26 amino acid residues in the sequence of IsPETase (amino acid sequence as shown in SEQ ID No.13) is a signal peptide. In order to prevent it from affecting the correct folding of the protein, the signal peptide needs to be removed in advance. Therefore, the signal peptide is not included in the IsPETase-4×Chimera recombinase.

[0013] The IsPETase-4×Chimera recombinant enzyme constructed in the present application has high activity and thermal stability, which makes up for the limitations of the natural IsPETase enzyme in practical applications, such as poor thermal stability and low reaction activity, and can be applied to PET hydrolysis catalytic reactions that are of great value to the environment and resources.

[0014] In combination with the first aspect, in some embodiments, the IsPETase-4×Chimera recombinase has an amino acid sequence: the amino acid sequence shown in SEQ ID No.2 is replaced by the amino acid sequence shown in SEQ ID No.7.

[0015] In combination with the first aspect, in some embodiments, the IsPETase-4×Chimera recombinase has an amino acid sequence: the amino acid sequence shown in SEQ ID No.3 is replaced by the amino acid sequence shown in SEQ ID No.9.

[0016] In combination with the first aspect, in some embodiments, the IsPETase-4×Chimera recombinase has an amino acid sequence: the amino acid sequence shown in SEQ ID No.4 is replaced by the amino acid sequence shown in SEQ ID No.12.

[0017] In combination with the first aspect, in some embodiments, the IsPETase-4×Chimera recombinase has an amino acid sequence: on the basis of IsPETase, at least two of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2, the amino acid sequence shown in SEQ ID No.3 and the amino acid sequence shown in SEQ ID No.4 are replaced, and at least one of the amino acid sequences shown in SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3 is replaced.

[0018] In combination with the first aspect, in some embodiments, the IsPETase-4×Chimera recombinase has an amino acid sequence: on the basis of IsPETase, at least three of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2, the amino acid sequence shown in SEQ ID No.3 and the amino acid sequence shown in SEQ ID No.4 are replaced, and the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, and the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9.

[0019] Exemplarily, the IsPETase-4×Chimera recombinase has an amino acid sequence as follows: on the basis of IsPETase, the amino acid sequence shown in SEQ ID No.1 is replaced with an amino acid sequence shown in SEQ ID No.5 or SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with an amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with an amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with an amino acid sequence shown in SEQ ID No.11 or SEQ ID No.12.

[0020] In the second aspect, the present application also provides the use of the above-mentioned IsPETase-4×Chimera recombinant enzyme in the hydrolysis of PET, including: adding PET to a glycine-NaOH buffer with a pH value of 8.0 to 10.0 and a concentration of 40mM (mmol / L) to 60mM so that the final concentration is 60mg / mL to 100mg / mL (that is, the ratio of the mass of PET (in mg) to the volume of the glycine-NaOH buffer (in mL) is 60 to 100); then adding IsPETase-4×Chimera recombinant enzyme to the above solution so that the final concentration of IsPETase-4×Chimera recombinant enzyme is 400nM (nmol / L) to 600nM; incubating for 1 to 3 days at a temperature of 30°C to 60°C and a rotation speed of 100rpm to 300rpm.

[0021] In a third aspect, the present application also provides a coding gene comprising a nucleotide sequence encoding the above-mentioned IsPETase-4×Chimera recombinase.

[0022] In a fourth aspect, the present application also provides a recombinant plasmid comprising the nucleotide sequence of the above-mentioned encoding gene.

[0023] In a fifth aspect, the present application also provides a method for constructing the above-mentioned recombinant plasmid, comprising the following steps:

[0024] Plasmids pET-22b-IsPETase, pET-22b-TfCut2 and pET-22b-LCC are used as templates respectively, and linear vector fragments corresponding to each template are obtained by PCR amplification; the linear vector fragments corresponding to each template are mixed with ligase respectively to form circular recombinant plasmids; the circular recombinant plasmids are transformed into T1 competent cells respectively, and recombinant plasmids pET-22b-IsPETase-cSP, recombinant plasmid pET-22b-TfCut2-cSP and recombinant plasmid pET-22b-LCC-cSP are obtained by ampicillin plate culture medium screening and plasmid extraction; the nucleotide sequence of the IsPETase-cSP gene in the recombinant plasmid pET-22b-IsPETase-cSP is shown in SEQ ID No.53, and the amino acid sequence of the IsPETase-cSP enzyme is shown in SEQ ID No.54; the nucleotide sequence of the TfCut2-cSP gene in the recombinant plasmid pET-22b-TfCut2-cSP is shown in SEQ ID No.55, and the amino acid sequence of the TfCut2-cSP enzyme is shown in SEQ ID No.56; the nucleotide sequence of the LCC-cSP gene in the recombinant plasmid pET-22b-LCC-cSP is shown in SEQ ID No.57, and the amino acid sequence of the LCC-cSP enzyme is shown in SEQ ID No.58;

[0025] At least two of the recombinant plasmids pET-22b-IsPETase-cSP, pET-22b-TfCut2-cSP and pET-22b-LCC-cSP are used as templates for PCR amplification, the obtained amplified fragments are connected, transformed into T1 competent cells, and the recombinant plasmid is obtained by screening with ampicillin plate culture medium and extracting the plasmid.

[0026] In a sixth aspect, the present application also provides an engineered bacterium, comprising the above-mentioned recombinant plasmid.

[0027] In a seventh aspect, the present application also provides a method for constructing the above-mentioned engineered bacteria, comprising: transforming the above-mentioned recombinant plasmid into BL21 (DE3) competent cells, spreading them on ampicillin plate culture medium, and obtaining positive recombinants, namely the engineered bacteria.

[0028] In an eighth aspect, the present application also provides the use of the above-mentioned engineering bacteria in degrading PET, comprising the following steps:

[0029] The engineered bacteria were cultured in LB liquid medium until OD600 was 0.7-0.9, 0.05%-0.2% (volume percentage v / v) of inducer IPTG (isopropyl-β-D-thiogalactopyranoside) was added, the temperature was lowered to 14° C.-20° C. to induce expression for 16 h-24 h, and the wet cells of the engineered bacteria were collected by centrifugation;

[0030] The wet cells of the engineered bacteria are subjected to a sterilization treatment, and cell debris are removed by centrifugation. The supernatant obtained by centrifugation is eluted using a Ni-NTA packed column with an elution buffer as an elution solvent, the eluate is collected, and the eluate is concentrated to obtain a protein concentrate;

[0031] The protein concentrate is added to a glycine-sodium hydroxide buffer having a pH value of 8.0 to 10.0 and a concentration of 40 mM to 60 mM to make the protein concentration 400 nM to 600 nM, and PET degradation is performed at 30° C. to 60° C. The concentration of glycine in the glycine-sodium hydroxide buffer is 50 mM to 200 mM.

[0032] Beneficial Effects

[0033] The beneficial effects of the present application are: the IsPETase-4×Chimera recombinant enzyme provided in the present application has high activity and thermal stability, and the thermal melting temperature Tm can be increased to 73.18°C, which is 26°C higher than the Tm of natural IsPETase, and the TPA production can reach up to 4925.75μM, which is much higher than the TPA production of wild-type PET hydrolase IsPETase, TfCut2, and LCC at the same temperature. The amino acid fragments of the recombinant enzyme come from different natural enzyme parent enzymes, but compared with the natural enzyme, the recombinant enzyme has acquired new functions that it does not have, which is of great significance for achieving efficient degradation of PET, and can be applied to the fields of plastic waste conversion, resource utilization, and environmental protection, and has a wide range of application value. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical solution and advantages of the present application more clear, the present application is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described here are only used to explain the present application and are not used to limit the present application.

[0035] The degradation of PET can reduce the environmental pollution it brings and obtain the high value-added product TPA. Enzyme treatment technology can play a role in the degradation of PET. At present, a variety of PET hydrolases have been discovered, such as esterase, lipase and cutinase, but the activity of these hydrolases at room temperature is very low. IsPETase can effectively hydrolyze PET at room temperature, but its hydrolysis of PET mainly occurs in the amorphous part, and the stability and activity of natural IsPETase at high temperature are relatively poor. Its activity will be mostly lost after incubation at 37°C for 24 hours, which is not enough to maintain efficient substrate degradation activity at higher reaction temperatures, which seriously limits its application range.

[0036] The present application is based on the study of IsPETase, combined with rational design and directed evolution, and its performance is changed by replacing its different domains with other amino acid sequences, thereby obtaining IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13) and at least one of the amino acid sequences as shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4 is replaced, wherein:

[0037] The amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5 or SEQ ID No.6;

[0038] The amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7 or SEQ ID No.8;

[0039] The amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9 or SEQ ID No.10;

[0040] The amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11 or SEQ ID No.12.

[0041] The examples of the present application also provide a method for constructing the above-mentioned IsPETase-4×Chimera recombinant enzyme and its application in hydrolyzing PET.

[0042] The present application also provides a gene encoding the recombinase.

[0043] The embodiments of the present application also provide a recombinant plasmid containing the above nucleotide sequence and a construction method thereof, as well as an engineered bacterium constructed using the recombinant plasmid.

[0044] The embodiments of the present application also provide a method for constructing the engineered bacteria and its application in degrading PET.

[0045] The solution of the present application is described below through specific embodiments.

[0046] Unless otherwise specified, the reagents in the following examples are commercially available or obtained according to methods known in the art.

[0047] Example 1

[0048] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.14.

[0049] Example 2

[0050] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.15.

[0051] Example 3

[0052] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.16.

[0053] Example 4

[0054] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is prepared by replacing the amino acid sequence shown in SEQ ID No.1 with the amino acid sequence shown in SEQ ID No.5 on the basis of IsPETase (amino acid sequence as shown in SEQ ID No.13), replacing the amino acid sequence shown in SEQ ID No.2 with the amino acid sequence shown in SEQ ID No.7, and replacing the amino acid sequence shown in SEQ ID No.3 with the amino acid sequence shown in SEQ ID No.9. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.17.

[0055] Example 5

[0056] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.18.

[0057] Example 6

[0058] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, and the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.10. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.19.

[0059] Example 7

[0060] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.10, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.20.

[0061] Example 8

[0062] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.10, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.21.

[0063] Example 9

[0064] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.8, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.22.

[0065] Example 10

[0066] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.8, and the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.23.

[0067] Embodiment 11

[0068] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.8, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.24.

[0069] Example 12

[0070] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.8, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.25.

[0071] Example 13

[0072] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.8, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.10, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.26.

[0073] Embodiment 14

[0074] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.27.

[0075] Embodiment 15

[0076] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is prepared by replacing the amino acid sequence shown in SEQ ID No.1 with the amino acid sequence shown in SEQ ID No.6 on the basis of IsPETase (amino acid sequence as shown in SEQ ID No.13), replacing the amino acid sequence shown in SEQ ID No.2 with the amino acid sequence shown in SEQ ID No.7, and replacing the amino acid sequence shown in SEQ ID No.4 with the amino acid sequence shown in SEQ ID No.11. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.28.

[0077] Example 16

[0078] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is prepared by replacing the amino acid sequence shown in SEQ ID No.1 with the amino acid sequence shown in SEQ ID No.6 on the basis of IsPETase (amino acid sequence as shown in SEQ ID No.13), replacing the amino acid sequence shown in SEQ ID No.2 with the amino acid sequence shown in SEQ ID No.7, and replacing the amino acid sequence shown in SEQ ID No.4 with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.29.

[0079] Embodiment 17

[0080] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is prepared by replacing the amino acid sequence shown in SEQ ID No.1 with the amino acid sequence shown in SEQ ID No.6 on the basis of IsPETase (amino acid sequence as shown in SEQ ID No.13), replacing the amino acid sequence shown in SEQ ID No.2 with the amino acid sequence shown in SEQ ID No.7, and replacing the amino acid sequence shown in SEQ ID No.3 with the amino acid sequence shown in SEQ ID No.9. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.30.

[0081] Embodiment 18

[0082] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.31.

[0083] Embodiment 19

[0084] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.32.

[0085] Embodiment 20

[0086] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, and the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.10. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.33.

[0087] Embodiment 21

[0088] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.10, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.34.

[0089] Embodiment 22

[0090] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.10, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.35.

[0091] Embodiment 23

[0092] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is prepared by replacing the amino acid sequence shown in SEQ ID No.1 with the amino acid sequence shown in SEQ ID No.6 on the basis of IsPETase (amino acid sequence as shown in SEQ ID No.13), replacing the amino acid sequence shown in SEQ ID No.2 with the amino acid sequence shown in SEQ ID No.8, and replacing the amino acid sequence shown in SEQ ID No.4 with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.36.

[0093] Embodiment 24

[0094] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is prepared by replacing the amino acid sequence shown in SEQ ID No.1 with the amino acid sequence shown in SEQ ID No.6 on the basis of IsPETase (amino acid sequence as shown in SEQ ID No.13), replacing the amino acid sequence shown in SEQ ID No.2 with the amino acid sequence shown in SEQ ID No.8, and replacing the amino acid sequence shown in SEQ ID No.3 with the amino acid sequence shown in SEQ ID No.9. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.37.

[0095] Embodiment 25

[0096] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.8, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.38.

[0097] Embodiment 26

[0098] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), and the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.8, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.39.

[0099] Embodiment 27

[0100] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is prepared by replacing the amino acid sequence shown in SEQ ID No. 2 with the amino acid sequence shown in SEQ ID No. 7 on the basis of IsPETase (amino acid sequence as shown in SEQ ID No. 13), and replacing the amino acid sequence shown in SEQ ID No. 3 with the amino acid sequence shown in SEQ ID No. 9. The nucleotide sequence encoding the recombinase is shown in SEQ ID No. 40.

[0101] Embodiment 28

[0102] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.41.

[0103] Embodiment 29

[0104] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.42.

[0105] Embodiment 30

[0106] An embodiment of the present application provides an IsPETase-4×Chimera recombinase with high activity and thermal stability. The recombinase is based on IsPETase (amino acid sequence as shown in SEQ ID No.13), wherein the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.10, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12. The nucleotide sequence encoding the recombinase is shown in SEQ ID No.43.

[0107] Embodiment 31

[0108] The present application provides the use of IsPETase-4×Chimera recombinant enzyme in Examples 1 to 30 in hydrolyzing PET:

[0109] A PET film (diameter ); adding IsPETase-4×Chimera recombinant enzyme to a final concentration of 400 nM to 600 nM; incubating at 30° C. to 60° C., 100 rpm to 300 rpm for 1 to 3 days.

[0110] Test Example 1

[0111] This test example examines the Tm values ​​of the IsPETase-4×Chimera recombinant enzymes of Examples 1 to 30 and their effects on PET films (diameter ) degradation effect.

[0112] The Tm value was measured using a Q-PCR instrument.

[0113] For PET film The degradation effect of PET film was investigated by the following method: PET film was added to 50 mM glycine-NaOH buffer with a pH of 9.0. IsPETase-4×Chimera recombinant enzyme was added to a final concentration of 500 nM, and incubated at 40°C to 60°C, 250 rpm for 1 day. The TPA yield in the reaction solution obtained after PET degradation was detected by high performance liquid chromatography (HPLC). The detection conditions of HPLC were: UV detector, characteristic absorption peak of 240 nm, ZORBAX Eclipse Plus C18 reverse phase column (5 μl, 250 mm×4.6 mm), mobile phase A was 0.1% formic acid aqueous solution, mobile phase B was acetonitrile, mobile phase B was increased from 5% acetonitrile to 70% acetonitrile within 20 minutes, column temperature was 30°C, injection volume was 10 μL, flow rate was 0.8 ml / min.

[0114] The Tm values ​​and TPA yields are shown in Table 1.

[0115] Table 1 Tm values ​​and TPA yields of IsPETase-4×Chimera recombinases of Examples 1 to 30

[0116]

[0117]

[0118] This test example also examined the Tm and TPA production of wild-type PET hydrolase IsPETase, TfCut2, and LCC using the same method, as shown in Table 2.

[0119] Table 2 Tm values ​​and TPA yields of wild-type PET hydrolase IsPETase, TfCut2, and LCC

[0120]

[0121] Embodiment 32

[0122] The present application provides a recombinant plasmid containing a gene encoding the IsPETase-4×Chimera recombinase in Examples 1 to 30 and a construction method:

[0123] 1. Construction of recombinant plasmids pET-22b-IsPETase-cSP, pET-22b-TfCut2-cSP and pET-22b-LCC-cSP

[0124] Construction of recombinant plasmid pET-22b-IsPETase: The wild-type PET hydrolase IsPETase gene (SEQ ID No. 44) was connected to the pET-22b plasmid to obtain.

[0125] Construction of recombinant plasmid pET-22b-TfCut2: The wild-type TfCut2 gene (SEQ ID NO.45) was connected to the pET-22b plasmid.

[0126] Construction of recombinant plasmid pET-22b-LCC: The wild-type LCC gene (SEQ ID NO.46) was connected to the pET-22b plasmid to obtain.

[0127] Among them, the source of the wild-type PET hydrolase IsPETase gene is: Ideonella sakaiensis (GI: 1028065175), the source of the wild-type TfCut2 gene is: Thermobifida fusca (GenBank: JN129500.1), and the source of the wild-type LCC gene is: uncultured bacteria (GenBank: HQ704839.1).

[0128] The pET-22b plasmid is a commercially available product.

[0129] The preparation method of the recombinant plasmid (recombinant plasmid pET-22b-IsPETase-cSP, pET-22b-TfCut2-cSP and pET-22b-LCC-cSP) comprises the following specific steps:

[0130] According to Beijing Quanshijin Biotechnology Co., Ltd. 2× According to the requirements of the FastPfuPCR SuperMix kit, the recombinant plasmids pET-22b-IsPETase, pET-22b-TfCut2 and pET-22b-LCC were used as templates, and the primers were designed as follows:

[0131] IsPETase-cSP-F:5'-GAGATATACATATGCAGACCAACCCCTACGCCCGCGGCCCGAA CC (SEQID No. 47);

[0132] IsPETase-cSP-R:5'-GTAGGGGTTGGTCTGCATATGTATATCTCCTTCTTAAAGTTAA AC (SEQID No. 48);

[0133] TfCut2-cSP-F:5'-GGAGATATAcatatgGCCAACCCCTACGAGCGCGGCCCCAACCCG (SEQ ID No. 49);

[0134] TfCut2-cSP-R:5'-CTCGTAGGGGTTGGCcatatgTATATCTCCTTCTTAAAGTTAAAC (SEQ ID No. 50);

[0135] LCC-cSP-F:5'-GGAGATATAcatatgGACGGAGTTCTCTGGCGAGTGCGAACCGCG (SE Q IDNo. ​​51);

[0136] LCC-cSP-R: 5'-CCAGAGAACTCCGTCcatatgTATATCTCCTTCTTAAAGTTAAAC (SEQ ID No. 52).

[0137] By PCR amplification, linear vector fragments of 6.2 kb, 6.2 kb and 6.2 kb corresponding to each template were obtained respectively; the linear vector fragments obtained by amplification of each template were mixed with ligase respectively, and circular recombinant plasmids were formed under the action of ligase (3 circular recombinant plasmids were obtained); the circular recombinant plasmids were transformed into T1 competent cells respectively, and recombinant plasmids pET-22b-IsPETase-cSP, pET-22b-TfCut2-cSP and pET-22b-LCC-cSP were obtained respectively through ampicillin plate culture medium screening, plasmid extraction and sequencing verification. The nucleotide sequence of the IsPETase-cSP (cut off signal peptide, cSP) gene in the recombinant plasmid pET-22b-IsPETase-cSP is shown in SEQ ID No.53, and the amino acid sequence of the IsPETase-cSP enzyme is shown in SEQ ID No.54; the nucleotide sequence of the TfCut2-cSP gene in the recombinant plasmid pET-22b-TfCut2-cSP is shown in SEQ ID No.55, and the amino acid sequence of the TfCut2-cSP enzyme is shown in SEQ ID No.56; the nucleotide sequence of the LCC-cSP gene in the recombinant plasmid pET-22b-LCC-cSP is shown in SEQ ID No.57, and the amino acid sequence of the LCC-cSP enzyme is shown in SEQ ID No.58;

[0138] The formula of ampicillin plate medium is: yeast extract 5g / L, tryptone 10g / L, sodium chloride 10g / L, agar powder 15g / L, ampicillin 50mg / L;

[0139] The PCR reaction system and PCR procedure were based on the 2× The requirements for the FastPfuPCR SuperMix Kit are shown in Table 3:

[0140] Table 3 PCR reaction system

[0141]

[0142] 2. Construction of a recombinant plasmid containing the gene encoding IsPETase-4×Chimera recombinase (taking Example 5 as an example)

[0143] Design and synthesize the primers required for recombination:

[0144] 4×chimera5-1-F:5'-CCGCCACTGCCAGctcgagCACCACCACCACCACCACTG (SEQ ID No. 59);

[0145] 4×chimera5-1-R:5'-GCTCCACGTACACCTTGCTGATGGAGCTCGGCAGG (SEQ ID No. 60);

[0146] 4×chimera5-2-F:5'-CCGAGCTCCATCAGCAAGGTGTACGTGGAGCTCGAC (SEQ ID No. 61);

[0147] 4×chimera5-2-R:5'-GGTGGTGGTGCTCGAGCTGGCAGTGGCGGTTGTTCGTC (SEQ ID No. 62);

[0148] The recombinant plasmid containing the IsPETase-4×Chimera recombinase gene encoding Example 5 was constructed by PCR technology (amplification system is the same as Table 3) and seamless connection according to the requirements of the seamless recombination kit. The steps are mainly divided into three steps: (1) using the recombinant plasmid pET-22b-TfCut2-cSP as a template, 4×chimera5-1-F and 4×chimera5-1-R as forward (upstream) and reverse (downstream) primers for PCR amplification (95°C for 2 min; 95°C for 20 s, 68°C for 20 s, 72°C for 5 min, 30 cycles; 72°C for 5 min), and the PCR product was digested with DMT enzyme, subjected to nucleic acid electrophoresis and gel excision recovery to obtain a purified gene fragment 1; (2) using the recombinant plasmid pET-22b-LCC-cSP as a template, 4×chimera 5-2-F and 4×chimera5-2-R were used as forward and reverse primers for PCR amplification (95°C for 2 min; 95°C for 20 s, 68°C for 20 s, 72°C for 5 min, 30 cycles; 72°C for 5 min). The PCR product was subjected to DMT enzyme digestion, nucleic acid electrophoresis and gel excision recovery to obtain purified gene fragment 2; (3) under the action of seamless recombinant ligase, gene fragment 1 and gene fragment 2 were connected and transformed into T1 competent cells. Through ampicillin plate culture medium screening, plasmid extraction and sequencing verification, a recombinant plasmid pET-22b-IsPETase-4×Chimera5 containing the IsPETase-4×Chimera recombinase gene encoding Example 5 was obtained; wherein the nucleotide sequence of the IsPETase-4×Chimera5 gene is shown in SEQ ID No.18.

[0149] The formula of the ampicillin plate medium is: 5 g / L yeast extract, 10 g / L tryptone, 10 g / L sodium chloride, 15 g / L agar powder, and 50 mg / L ampicillin. The seamless recombinant ligase is a seamless cloning enzyme, and the application uses 2X MultiF Seamless Assembly Mix produced by ABclonal.

[0150] When constructing the IsPETase-4×Chimera recombinase in other embodiments, the primers required for recombination are designed and synthesized corresponding to each recombinase (see Table 4), and the recombinant plasmids pET-22b-IsPETase-cSP, recombinant plasmid pET-22b-TfCut2-cSP and recombinant plasmid pET-22b-LCC-cSP in step 1 are used to construct recombinant plasmids containing genes encoding each recombinase using seamless connection and PCR technology according to the requirements of the seamless recombination kit.

[0151] Table 4 Primers and templates corresponding to IsPETase-4×Chimera recombinase of Examples 1 to 30

[0152]

[0153]

[0154]

[0155]

[0156]

[0157]

[0158]

[0159] Example 33 This example of the application provides an engineering bacterium containing the recombinant plasmid of Example 32 and a method for constructing the same:

[0160] The recombinant plasmid of Example 32 was transformed into BL21 (DE3) competent cells and spread on ampicillin plate culture medium to obtain positive recombinants, which are engineered bacteria containing the recombinant plasmid of Example 32.

[0161] Embodiment 34

[0162] The present application example provides the method for inducing expression of the engineering bacteria and purifying the target protein of Example 33:

[0163] The engineered bacteria of Example 33 were inoculated into LB liquid medium and cultured overnight at 37°C and 220 r / min; the overnight culture solution was inoculated into fresh LB liquid medium at a 1% inoculation rate, and cultured at 37°C and 220 r / min until OD600 was about 0.8, 0.1% (v / v) of inducer IPTG was added, and the temperature was lowered to 16°C to induce expression for 20 hours to obtain a fermentation culture. The fermentation culture was centrifuged at 4000 rpm for 15 minutes to collect wet cells of the engineered bacteria.

[0164] The wet cells of the engineered bacteria were resuspended in a lysis buffer and the resuspended wet cells were lysed using a high-pressure cell disruptor. The lysed bacterial solution was centrifuged at 10,000 rpm for 60 minutes to remove cell debris. The supernatant obtained by centrifugation was adsorbed with a Ni-NTA column to adsorb the target protein, and the non-specifically adsorbed impurities were washed with a washing buffer. The target protein was eluted with an elution buffer, and the eluate was concentrated in a protein concentrator.

[0165] The formula of LB liquid medium is: yeast extract 5g / L, tryptone 10g / L, sodium chloride 10g / L;

[0166] The formula of the lysis buffer is: 50 mM Tris-HCl, 150 mM NaCl, 10 mM Imidazole, pH = 7.5;

[0167] The formula of the washing buffer is: 50mM Tris-HCl, 150mM NaCl, 20mM Imidazole, pH = 7.5;

[0168] The formula of the elution buffer is: 50 mM Tris-HCl, 300 mM NaCl, 300 mM Imidazole, pH = 7.5.

[0169] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.

Claims

1. An IsPETase-4×Chimera recombinase, characterized in that The amino acid sequence of the IsPETase-4×Chimera recombinase is as follows: IsPETase is replaced with at least one of the amino acid sequences shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4, wherein: The amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5 or SEQ ID No.6; The amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7 or SEQ ID No.8; The amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9 or SEQ ID No.10; The amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11 or SEQ ID No.

12.

2. The IsPETase-4×Chimera recombinant enzyme according to claim 1, characterized in that The IsPETase-4×Chimera recombinase has an amino acid sequence as follows: the amino acid sequence shown in SEQ ID No. 2 is replaced by the amino acid sequence shown in SEQ ID No. 7; and / or The amino acid sequence shown in SEQ ID No.3 is replaced by the amino acid sequence shown in SEQ ID No.9; and / or The amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.

12.

3. The IsPETase-4×Chimera recombinant enzyme according to claim 1 or 2, characterized in that The IsPETase-4×Chimera recombinase has an amino acid sequence as follows: IsPETase is replaced with at least two of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2, the amino acid sequence shown in SEQ ID No.3 and the amino acid sequence shown in SEQ ID No.4, and includes replacing at least one of the amino acid sequences shown in SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3; or Based on IsPETase, at least three of the amino acid sequence shown in SEQ ID No.1, the amino acid sequence shown in SEQ ID No.2, the amino acid sequence shown in SEQ ID No.3 and the amino acid sequence shown in SEQ ID No.4 are replaced, and the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, and the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.

9.

4. The IsPETase-4×Chimera recombinant enzyme according to claim 1 or 2, characterized in that The IsPETase-4×Chimera recombinase has an amino acid sequence of: On the basis of IsPETase, the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.5, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.12; or On the basis of IsPETase, the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.11; or On the basis of IsPETase, the amino acid sequence shown in SEQ ID No.1 is replaced with the amino acid sequence shown in SEQ ID No.6, the amino acid sequence shown in SEQ ID No.2 is replaced with the amino acid sequence shown in SEQ ID No.7, the amino acid sequence shown in SEQ ID No.3 is replaced with the amino acid sequence shown in SEQ ID No.9, and the amino acid sequence shown in SEQ ID No.4 is replaced with the amino acid sequence shown in SEQ ID No.

12.

5. Use of the IsPETase-4×Chimera recombinant enzyme according to any one of claims 1 to 4 in hydrolyzing PET, characterized in that: include: Add PET to a glycine-NaOH buffer solution with a pH value of 8.0 to 10.0 and a concentration of 40 mM to 60 mM to make a final concentration of 60 mg / mL to 100 mg / mL; then add the IsPETase-4×Chimera recombinant enzyme to the above solution to make the final concentration of the IsPETase-4×Chimera recombinant enzyme be 400 nM to 600 nM; incubate at a temperature of 30°C to 60°C and a rotation speed of 100 rpm to 300 rpm for 1 to 3 days.

6. A coding gene, characterized in that It comprises a nucleotide sequence encoding the IsPETase-4×Chimera recombinase according to any one of claims 1 to 4.

7. A recombinant plasmid, characterized in that: Comprising the nucleotide sequence encoding the gene according to claim 6.

8. The method for constructing the recombinant plasmid according to claim 7, characterized in that: The method comprises the following steps: using plasmid pET-22b-IsPETase, plasmid pET-22b-TfCut2 and plasmid pET-22b-LCC as templates, respectively, obtaining linear vector fragments corresponding to each template by PCR amplification; mixing the linear vector fragments corresponding to each template with ligase respectively to form circular recombinant plasmids; transforming the circular recombinant plasmids into T1 competent cells respectively, and obtaining recombinant plasmid pET-22b-IsPETase-cSP, recombinant plasmid pET-22b-TfCut2-cSP and recombinant plasmid pET-22b-LCC-cSP by ampicillin plate culture medium screening and plasmid extraction; the nucleotide sequence of the IsPETase-cSP gene in the recombinant plasmid pET-22b-IsPETase-cSP is shown in SEQ ID No.53, and the amino acid sequence of the IsPETase-cSP enzyme is shown in SEQ ID No.54; the nucleotide sequence of the TfCut2-cSP gene in the recombinant plasmid pET-22b-TfCut2-cSP is shown in SEQ ID No.55, and the amino acid sequence of the TfCut2-cSP enzyme is shown in SEQ ID No.56; the nucleotide sequence of the LCC-cSP gene in the recombinant plasmid pET-22b-LCC-cSP is shown in SEQ ID No.57, and the amino acid sequence of the LCC-cSP enzyme is shown in SEQ ID No.58; At least two of the recombinant plasmids pET-22b-IsPETase-cSP, pET-22b-TfCut2-cSP and pET-22b-LCC-cSP are used as templates for PCR amplification, the obtained amplified fragments are connected, transformed into T1 competent cells, and the recombinant plasmid is obtained by screening with ampicillin plate culture medium and extracting the plasmid.

9. An engineered bacterium, characterized in that: Comprising the recombinant plasmid described in claim 7.

10. The method for constructing an engineered bacterium according to claim 9, characterized in that: include: The recombinant plasmid described in claim 7 is transformed into BL21 (DE3) competent cells, and spread on ampicillin plate culture medium to obtain positive recombinants, which are the engineered bacteria.

11. The use of the engineering bacteria according to claim 9 in the degradation of PET, characterized in that: The following steps are involved: The engineered bacteria were cultured in LB liquid medium until OD600 was 0.7-0.9, 0.05%-0.2% of inducer IPTG was added, the temperature was lowered to 14°C-20°C to induce expression for 16h-24h, and the wet cells of the engineered bacteria were collected by centrifugation; The wet cells of the engineered bacteria are subjected to a sterilization treatment, and cell debris are removed by centrifugation. The supernatant obtained by centrifugation is eluted using a Ni-NTA packed column with an elution buffer as an elution solvent, the eluate is collected, and the eluate is concentrated to obtain a protein concentrate; The protein concentrate is added to a glycine-sodium hydroxide buffer having a pH value of 8.0 to 10.0 and a concentration of 40 mM to 60 mM to make the protein concentration 400 nM to 600 nM, and PET degradation is performed at 30° C. to 60° C. The concentration of glycine in the glycine-sodium hydroxide buffer is 50 mM to 200 mM.

Citation Information

Cited By

  • Chimeric enzyme for degrading PET (Polyethylene Terephthalate) as well as related biological material and application thereof

    CN119662599A